genedrive

This December, Genedrive are excited to be attending the UK Stroke Forum! Visit our stand to discover how our innovative genetic testing products can guide antiplatelet therapy by informing clinicians of CYP2C19 metaboliser status Book your place: https://lnkd.in/eCsMrSA #GDR #POCT #Stroke #patientsafety #pointofcare #pharmacogenomics #pharmacogenetics #StrokeAwareness

🔔 We are looking forward to meeting you at MEDICA - Leading International Trade Fair in just 2 WEEKS! Visit our genedrive stand in Hall 1 F09-1 where Patrick Breen Andrew Burns Claire Newton Jonathan Dale will be happy to show you how our Genedrive pharmacogenetic tests are being used to guide treatment in time critical situations. Contact enquiries@genedrive.com to book a meeting #GDR #gambica #medica2024 #diagnostics #pharmacogenetics #poctesting #ivd

⭐ #WorldStrokeDay reminds us of the importance of acting FAST, using the Face, Arms, Speech, and Time warning signs that can help identify a stroke. Around 100,000 strokes happen each year in the UK – that means a stroke strikes every 5 minutes. But clopidogrel, a common antiplatelet therapy, does not work for everyone. Around 1 in 3 people have variation in the CYP2C19 gene, which alters how clopidogrel is processed. Genetic testing for CYP2C19 status can improve stroke patient care. 🔗 Read the NICE guidance: https://lnkd.in/eRTQ4v2S #GDR #Stroke #Pharmacogenomics #POCT #StrokeAwareness #Diagnostics

The Development and Validation of Technology for Time Critical Genomic Testing (DEVOTE) Programme brings together academic, industry and clinical partners from across the region, and aims to create societal and economic impact by realising the potential of genomic testing for all. Prof. Bill Newman, Professor of Translational Genomic Medicine at The University of Manchester and Consultant in Genomic Medicine at Manchester University NHS Foundation Trust, and a researcher with the NIHR Manchester Biomedical Research Centre (BRC), said: “This is a great opportunity to enhance GM’s status as a world leader in creating genetic tests that can give rapid results in minutes. We expect that the DEVOTE projects will lead to the adoption of new tests by the NHS to make drug prescription safer and more effective. This will be good for patients and good for GM by creating jobs and a centre for investment in this cutting-edge science.” Find out more about DEVOTE and how this programme is underpinned by a shared ethos to reduce inequalities across communities, and building on assets already in existence within the #GreaterManchester system: https://bit.ly/3BOuD7m The DEVOTE programme is led by The University of Manchester and supported by Health Innovation Manchester in partnership with: 🤝 Manchester University NHS Foundation Trust 🤝 Health Innovation Manchester 🤝 genedrive 🤝 Chromition 🤝 APIS Assay Technologies Ltd. 🤝 EMQN CIC #weareHInM #DEVOTE #GM #innovation #genomics #genetics

Welcome Charlotte Corner, Genedrive’s Business Development Executive! Charlotte is helping bring our point-of-care solutions to clinicians around the UK. It’s great to have you on the team! #GDR #POCT #Pharmacogenetics #Pharmacogenomics #Diagnostics #genetictesting

In just a few weeks, Genedrive will be attending POCT-for-Scot conference in Glasgow! We can't wait to see you there 📧 Email enquiries@genedrive.com to book a meeting #GDR #pharmacogenetics #POCT #pointofcare #diagnostics #medtech

We’re excited to announce the release of our new products for MT-RNR1 Point-of-Care Testing. MT-RNR1 testing is used in an acute clinical setting to detect a genetic variant associated with an increased susceptibility of neonatal hearing loss after treatment with aminoglycoside antibiotics. The low frequency of the MT-RNR1 variant makes it difficult to verify testing methodologies, therefore we have developed an EQA and separate device verification samples tailored for the genedrive MT-RNR1 ID Kit that tests for the MT-RNR1 m.1555A>G variant.  👉 The EQA offers patient-like samples that you can process in the same way as a cheek/buccal swab. With an annual subscription, you will receive three EQA samples every two months (18 in a year). These will allow you to verify the ongoing accuracy of your tests, to make sure you are providing the most accurate diagnosis possible. 👉 Our device verification samples are suitable for either the initial verification of newly purchased instruments or for periodic verification as required by your quality manual. Visit our website for more information about our POCT schemes: https://lnkd.in/e2WtvgGV You must have an EMQN account to purchase the Device Verification Samples. More information can be found by searching our online catalogue for "DVS". #emqn #eqa #qualityassurance #genetics #poct #moleculardiagnostics #pharmacogenetics #newbornscreening

🔔 4 weeks to go, the countdown to MEDICA - Leading International Trade Fair 2024 is on! Visit our genedrive stand in Hall 1 F09-1 where Patrick Breen Andrew Burns Claire Newton and Jonathan Dale will be happy to show you how our Genedrive pharmacogenetic tests are being used to guide treatment in time critical situations. #GDR #gambica #medica2024 #diagnostics #pharmacogenetics #poctesting #ivd

🔔 4 weeks to go, the countdown to @Medica 2024 is on! Visit our genedrive stand in Hall 1 F09-1 where Patrick Breen Andrew Burns Claire Newton and Jonathan Dale will be happy to show you how our Genedrive pharmacogenetic tests are being used to guide treatment in time critical situations. #GDR #gambica #medica2024 #diagnostics #pharmacogenetics #poctesting #ivd

💡 If you are one of our existing customers and require any assistance, you can contact support@genedrive.com 👍 This allows all of our support team to see your enquiry, ensuring your problem is resolved as quickly as possible. 📧 support@genedrive.com #GDR